Zimmer Biomet stock (US98956P1021): shares react to Q1 2026 results and updated 2026 outlook

Zimmer Biomet has presented its Q1 2026 figures and updated guidance, sending the orthopedic specialist’s stock into focus among US investors. What is behind the latest numbers and how does the business model generate revenue?

Zimmer Biomet has come back into the spotlight after reporting first?quarter 2026 results and updating its full?year outlook for 2026, with investors reassessing the orthopedic group’s recovery trajectory in elective procedures, according to the company’s earnings release of 05/07/2026 and accompanying materials published on its investor relations website on the same day.Zimmer Biomet press release as of 05/07/2026

In its Q1 2026 update, Zimmer Biomet reported year?over?year revenue growth for the quarter and discussed trends in reconstructive implants and sports medicine, while also fine?tuning its 2026 financial guidance ranges, according to the detailed quarterly results presentation published on 05/07/2026.Zimmer Biomet investor presentation as of 05/07/2026

As of: 19.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Zimmer Biomet Holdings
• Sector/industry: Medical technology, orthopedic implants
• Headquarters/country: Warsaw, Indiana, United States
• Core markets: North America, Europe, Asia?Pacific hospitals and surgical centers
• Key revenue drivers: Knee and hip reconstruction, trauma devices, sports medicine and biologics
• Home exchange/listing venue: New York Stock Exchange (ticker: ZBH)
• Trading currency: US dollar (USD)

Zimmer Biomet: core business model

Zimmer Biomet operates as a global medical technology company focused on musculoskeletal healthcare, supplying orthopedic surgeons and hospitals with implants, instruments and digital solutions that support joint replacement, trauma repair and related procedures, according to its corporate profile updated on 03/14/2026.Zimmer Biomet company overview as of 03/14/2026

The business model centers on developing, manufacturing and marketing knee and hip replacement systems, extremities and trauma products, as well as surgical robotics and navigation platforms, with revenue generated primarily through product sales to hospitals and group purchasing organizations, according to the firm’s 2025 annual report filed on 02/23/2026.Zimmer Biomet annual report as of 02/23/2026

Recurring demand is supported by demographic trends such as population aging and osteoarthritis prevalence, while the company seeks to differentiate itself via implant design, surgeon training and perioperative digital tools that can help streamline workflows in operating rooms, according to management’s strategic commentary during its Q1 2026 earnings call held on 05/07/2026.Zimmer Biomet earnings call materials as of 05/07/2026

Main revenue and product drivers for Zimmer Biomet

Zimmer Biomet’s largest revenue contribution continues to come from knee replacement systems, where the Persona and NexGen product families address a broad spectrum of patient anatomies and surgical techniques, according to the company’s 2025 Form 10?K filed with the SEC on 02/23/2026.SEC filing as of 02/23/2026

Hip reconstruction products, including primary and revision systems with different bearing surfaces, represent the second?largest business line, while the trauma and extremities segment provides plates, screws and nails for fracture fixation, contributing to a diversified orthopedic portfolio, according to segment disclosures in the same 2025 annual report filed on 02/23/2026.Zimmer Biomet annual report as of 02/23/2026

Beyond implants, Zimmer Biomet is investing in sports medicine, biologics and its Rosa robotic platform, which is designed to assist surgeons in knee and other procedures by providing real?time data and precise instrumentation, according to the company’s product portfolio overview updated on 04/10/2026.Zimmer Biomet product overview as of 04/10/2026

Revenue mix is geographically diversified, with a strong base in the United States and significant contributions from Europe and Asia?Pacific, where Zimmer Biomet works with local distributors and direct sales forces to reach hospitals and clinics, according to regional revenue tables in the 2025 Form 10?K filed on 02/23/2026.SEC filing as of 02/23/2026

Why Zimmer Biomet matters for US investors

For US investors, Zimmer Biomet represents exposure to the orthopedic segment of the healthcare industry, which historically has been influenced by procedure volumes, reimbursement frameworks and innovation cycles in surgical techniques, according to commentary from the company’s management and sector analyses summarizing musculoskeletal markets on 04/05/2026.Zimmer Biomet investor information as of 04/05/2026

The stock is listed on the New York Stock Exchange under the ticker ZBH, and its performance can be affected by macro factors such as US hospital capital spending, elective surgery trends and insurance coverage dynamics, in addition to company?specific execution and product launches, according to market commentary published by major US financial outlets on 05/08/2026.NYSE data as of 05/08/2026

For investors with a focus on medical technology, Zimmer Biomet is often considered alongside peers in joint reconstruction and trauma devices, with relative valuation and margin development closely watched after each quarterly earnings release, according to sector reviews from established financial news services on 05/09/2026.Reuters company profile as of 05/09/2026

Conclusion

Zimmer Biomet’s latest Q1 2026 results and adjusted outlook keep attention on how the orthopedic specialist balances growth in joint reconstruction with investments in robotics, sports medicine and digital tools, while navigating hospital spending patterns and reimbursement structures in key markets. For US investors, the New York?listed stock offers focused exposure to musculoskeletal healthcare, but developments in procedure volumes, regulatory requirements and competitive dynamics can influence earnings trajectories from quarter to quarter, so ongoing monitoring of company disclosures and sector news remains important.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.